A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 16 Nov 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 13 Sep 2016 Status changed from recruiting to active, no longer recruiting.